unknown
Stage
About
Aeromics is a clinical-stage pharmaceutical company developing an intravenously administered aquaporin-4 inhibitor (AER-271) to prevent and treat cerebral edema in patients suffering from severe acute ischemic stroke.
Explore Aeromics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.